New clinical trial reforms to speed access

The Medicines and Healthcare products Regulatory Agency (MHRA) alongside the Health Research Authority (HRA) is set to introduce extensive clinical trial reforms, the most significant in over two decades. These changes, effective from 28 April 2026, aim to enable quicker patient access to innovative treatments while maintaining strict safety standards. The reforms will simplify the initiation of lower-risk studies and incorporate modern methodologies, such as leveraging early safety data from international studies and computer model simulations that can predict the behaviour of new medications before they undergo patient trials.

The MHRA and HRA have been working towards a more streamlined approval process, which has already seen a reduction in clinical trial set-up times from 169 days to 122 days for studies undergoing combined safety and ethical reviews. The revised combined review process is now completed in an average of just 41 days, marking a significant improvement compared to previous years. Dr Zubir Ahmed, Health Innovation and Safety Minister, noted “this is a landmark moment for patients, researchers, and our thriving life sciences sector that will make a real, tangible difference for thousands of people waiting for new treatments.”

The reforms include innovations such as the Route B substantial modification pathway, which tested a faster, risk-proportionate assessment approach during a pilot from October 2025 to March 2026. This pathway, which will be mandated from the end of April 2026, allows for automatic approval of eligible modifications unless safety concerns arise within 14 days.

Consultation with a diverse range of stakeholders, including patients, researchers, and industry experts, has shaped these new regulations which prioritise participant safety while enhancing access and transparency in clinical research. Lawrence Tallon, MHRA Chief Executive, expressed optimism, saying “these reforms to clinical trial regulations are a boost both for patients and industry investment in R&D in this country.”

With greater transparency, the updated regulations will also make it mandatory to register clinical trials and publicly share summary results. Matt Westmore, Chief Executive of the HRA, highlighted the framework’s dual focus on accelerating research and prioritising patient needs, stating “the reforms are designed to speed up access to new medicines and boost the UK life sciences economy.”

The MHRA is launching a Clinical Trials (CT) Hub to provide guidance for sponsors adjusting to the new regulations, facilitating smoother transitions to the updated processes. The collective efforts of the MHRA and HRA are positioned to make the UK a more appealing location for international clinical research, promising quicker patient access to cutting-edge treatments.